Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals

doi:10.4254/wjh.v17.i10.110430

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-3)

Sum=5

Oct 27, 2025 (publication date) through Oct 27, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Oct 27, 2025; 17(10): 110430
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110430

Sex-related differences in treatment outcomes of chronic hepatitis C with direct-acting antivirals

Gemechu Dereje Feyissa

Gemechu Dereje Feyissa, Department of Public Health, Faculty of Health Sciences, Rift Valley University, Adama 1715, Oromīa, Ethiopia

Author contributions: Feyissa GD has played important and indispensable roles in the manuscript preparation, read and approved the final version of the manuscript to be published.

Conflict-of-interest statement: There are no conflicts of interest.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Gemechu Dereje Feyissa, Assistant Professor, Department of Public Health, Faculty of Health Sciences, Rift Valley University, Hangatu District, Dabe Sub-city, Adama 1715, Oromīa, Ethiopia. gemechudereje80@gmail.com

Received: June 7, 2025
Revised: June 19, 2025
Accepted: August 22, 2025
Published online: October 27, 2025
Processing time: 143 Days and 18.1 Hours

Core Tip

Core Tip: Sex influences the epidemiology, progression, and treatment outcomes of chronic hepatitis C. Women exhibit lower body mass index, less genotype 3 infection, and fewer hepatitis B virus/human immunodeficiency virus coinfections compared to men. They have slower liver fibrosis progression and achieve higher sustained virologic response rates with direct-acting antivirals. However, postmenopausal women report more treatment-related adverse events. Recognizing these sex- and reproductive status-related differences is crucial to optimize personalized management and improve therapeutic outcomes in chronic hepatitis C patients.